President
iXCells Biotechnologies
San Diego, California
Nianwei Lin, PhD, is the President and Co-Founder of iXCells Biotechnologies. He received his Ph.D. in genetics from the College of Medicine at the University of Florida. In 2011, Nianwei started his postdoctoral training at Sanford-Burnham Medical Research Institute. Nianwei joined DSRD team at Pfizer as a postdoctoral fellow in August 2014, with his work focused on effects of lysosomal dysfunction on membrane trafficking and signal transduction, as well as the implication in toxicity, efficacy and resistance development. In 2014, Nianwei and his business partners founded iXCells Biotechnologies, a cell biology and cell technology company dedicated to providing innovative pre-clinical drug discovery solutions with the focus on disease relevant cellular models enabling technologies and services to the academic, biotech and pharma communities to accelerate drug discovery processes. The company offers the customers access to high quality primary and iPSC derived cells, custom iPSC services, functional bioassay development and execution. The company is specialized in development of Disease-in-a-dish models with its expertise in iPSC engineering and primary cell isolation for pre-clinical applications, including toxicology testing, personalized medicine development, target-based or phenotypic screening, etc..
Disclosure information not submitted.
Executive Track - Cell and Gene Therapies at the Intersection of Business and Science
Tuesday, May 14, 2024
9:30 AM – 11:00 AM PT